Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Waverley Pharma Inc V.WAVE

Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development, and commercialization of human therapeutics focused on oncology. The Company is focused on the generic oncology injectable market in Europe, the United Kingdom (UK), and North America. The Company, through its subsidiaries, has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited, which has granted the Company an exclusive territorial license to market and sell capecitabine in the UK and Germany as well as a non-exclusive territorial license to market and sell temozolomide and erlotinib in the UK. Its generic oncology products include bortezomib and pemetrexed. Bortezomib is an injectable generic chemotherapy drug, developed for the treatment of multiple myeloma and mantle cell lymphoma. Pemetrexed is an injectable generic chemotherapy drug, developed for the treatment of non-small cell lung cancer and pleural mesothelioma.


TSXV:WAVE - Post by User

Post by Horn1369on Aug 04, 2020 1:11pm
152 Views
Post# 31362089

Revenue from UK's NHS alone should be a big boost.

Revenue from UK's NHS alone should be a big boost.For the share price. We should see the numbers from EU in next Qs. GL


Products:

Waverley Pharma Inc. has a collaboration with Reliance Life Sciences Private Limited (RLS) part of a conglomerate based in Mumbai, India, for the commercialization of a number of oncology drugs for the United States and European markets.

Drugs for sale in Europe: 

Capecitabine:Capecitabine is manufactured by RLS, and the binding contracts with the UK National Health Service for the supply of capecitabine have been transferred to Waverley Pharma.  The product is approved in Germany and Waverley Pharma is seeking a sales and marketing partner. 

Temozolomide: Temozolomide is manufactured by RLS, and the binding contracts with the UK National Health Service for the supply of temozolomide have been transferred to Waverley pharma. 

Erlotinib: Erlotinib is manufactured by RLS.  Waverley Pharma has a binding contract with the U.K. National Health Service for the supply of Erlotinib.

How much money does the NHS spend on cancer?

Expenditure on cancer servicesIn nominal terms (the amount of money spent each year), spending had increased by 40% from £69.7 billion to £94.8 billion.
<< Previous
Bullboard Posts
Next >>